Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 28 Mar 2017 |
| Articles of Association for Genmab A/S | 1 Mar 2017 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 28 Feb 2017 |
| Genmab A/S Summons Annual General Meeting | 27 Feb 2017 |
| CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma | 24 Feb 2017 |